Carfilzomib/pomalidomide single-agent or in combination with other agents for the management of relapsed/refractory multiple myeloma: a meta-analysis of 37 trials

PURPOSE: The use of carfilzomib/pomalidomide single-agent or in combination with other agents in patients with refractory/relapsed multiple myeloma (RRMM) was not clearly clarified in clinical practice. We sought to compile the available clinical reports to better understand the efficacy and safety...

Descripción completa

Detalles Bibliográficos
Autores principales: Zou, Yandun, Ma, Xiaoyan, Yu, Haiying, Hu, Chunling, Fan, Limei, Ran, Xuehong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5503655/
https://www.ncbi.nlm.nih.gov/pubmed/27458170
http://dx.doi.org/10.18632/oncotarget.10768

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5503655/
https://www.ncbi.nlm.nih.gov/pubmed/27458170
http://dx.doi.org/10.18632/oncotarget.10768

Ejemplares similares